BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 19100909)

  • 21. Stress and mTORture signaling.
    Reiling JH; Sabatini DM
    Oncogene; 2006 Oct; 25(48):6373-83. PubMed ID: 17041623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.
    Bracho-Valdés I; Moreno-Alvarez P; Valencia-Martínez I; Robles-Molina E; Chávez-Vargas L; Vázquez-Prado J
    IUBMB Life; 2011 Oct; 63(10):896-914. PubMed ID: 21905202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Architecture of human mTOR complex 1.
    Aylett CH; Sauer E; Imseng S; Boehringer D; Hall MN; Ban N; Maier T
    Science; 2016 Jan; 351(6268):48-52. PubMed ID: 26678875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
    Fingar DC; Blenis J
    Oncogene; 2004 Apr; 23(18):3151-71. PubMed ID: 15094765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
    Sarbassov DD; Ali SM; Kim DH; Guertin DA; Latek RR; Erdjument-Bromage H; Tempst P; Sabatini DM
    Curr Biol; 2004 Jul; 14(14):1296-302. PubMed ID: 15268862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells.
    Fuhler GM; Tyl MR; Olthof SG; Lyndsay Drayer A; Blom N; Vellenga E
    Eur J Haematol; 2009 Sep; 83(3):235-45. PubMed ID: 19341427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
    Corradetti MN; Guan KL
    Oncogene; 2006 Oct; 25(48):6347-60. PubMed ID: 17041621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular organization of target of rapamycin complex 2.
    Wullschleger S; Loewith R; Oppliger W; Hall MN
    J Biol Chem; 2005 Sep; 280(35):30697-704. PubMed ID: 16002396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR substrate phosphorylation in growth control.
    Battaglioni S; Benjamin D; Wälchli M; Maier T; Hall MN
    Cell; 2022 May; 185(11):1814-1836. PubMed ID: 35580586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR and the control of whole body metabolism.
    Polak P; Hall MN
    Curr Opin Cell Biol; 2009 Apr; 21(2):209-18. PubMed ID: 19261457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [TOR-centric concept of regulation mitogenic, metabolic and energetic signal processing in cell].
    Zubova SG; Shitikova ZhV; Pospelova TV
    Tsitologiia; 2012; 54(8):589-602. PubMed ID: 23074850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
    Gibbons JJ; Abraham RT; Yu K
    Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nutrient sensing and TOR signaling in yeast and mammals.
    González A; Hall MN
    EMBO J; 2017 Feb; 36(4):397-408. PubMed ID: 28096180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The TOR signalling network from yeast to man.
    De Virgilio C; Loewith R
    Int J Biochem Cell Biol; 2006; 38(9):1476-81. PubMed ID: 16647875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mammalian target of rapamycin pathway and its role in molecular nutrition regulation.
    Lian J; Yan XH; Peng J; Jiang SW
    Mol Nutr Food Res; 2008 Apr; 52(4):393-9. PubMed ID: 18306429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR in Brain Physiology and Pathologies.
    Bockaert J; Marin P
    Physiol Rev; 2015 Oct; 95(4):1157-87. PubMed ID: 26269525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic control by target of rapamycin and autophagy during ageing - a mini-review.
    Markaki M; Tavernarakis N
    Gerontology; 2013; 59(4):340-8. PubMed ID: 23594965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of PRAS40 in Akt and mTOR signaling in health and disease.
    Wiza C; Nascimento EB; Ouwens DM
    Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1453-60. PubMed ID: 22354785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of the TOR pathway and its role in cancer.
    Beauchamp EM; Platanias LC
    Oncogene; 2013 Aug; 32(34):3923-32. PubMed ID: 23246968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolutionary Conservation of the Components in the TOR Signaling Pathways.
    Tatebe H; Shiozaki K
    Biomolecules; 2017 Nov; 7(4):. PubMed ID: 29104218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.